Human papillomavirus is commonly present in psoriatic skin and normal skin samples from healthy subjects.

E. Viviano,L. Giovannelli,E. Martorana,M. C. Migliore,V. Caputo,N. Romano

DOI: https://doi.org/10.1016/J.JDERMSCI.2006.09.011

2007-02-01

Abstract:

What problem does this paper attempt to address?

Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: A retrospective study and meta-analysis.

Jing Chen,Rui Wang,Bo Zhang,Xingguang Lin,Juncheng Wei,Yao Jia,Ye Yin,Shuangmei Ye,Tao Zhu,Gang Chen,Yongxun Yuan,Weiguo Lu,Kezhen Li

DOI: https://doi.org/10.1016/j.ajog.2016.04.023

IF: 9.8

2016-01-01

American Journal of Obstetrics and Gynecology

Abstract:BACKGROUND: The safety of ovarian preservation remains uncertain in women with cervical adenocarcinoma and significant risk factors for ovarian metastases vary among different studies. OBJECTIVE: We sought to evaluate the impact of ovarian preservation on prognosis in women with cervical adenocarcinoma and to assess clinical factors associated with ovarian metastases. STUDY DESIGN: A retrospective study of 194 women with cervical adenocarcinoma was conducted and 159 women were followed up until the end of the study. To compare the impact of ovarian preservation on prognosis, women with successful follow-up were studied, including 33 women with ovarian preservation and 126 women who underwent bilateral salpingo-oophorectomy. For women who underwent radical hysterectomy, pelvic lymphadenectomy, and bilateral salpingooophorectomy, the risk factors for ovarian metastases were identified. A meta-analysis of the literature was carried out to further validate the findings. RESULTS: There was no significant difference in survival between women with bilateral salpingo-oophorectomy and ovarian preservation (P = .423 for disease-free survival; P = .330 for overall survival). Tumor size (>4 cm), deep cervical stromal invasion, and lymph node metastasis were significant independent prognostic factors related to poor disease-free survival, and lymph node metastasis was significantly associated with overall survival. Of 153 women with cervical adenocarcinoma who underwent bilateral salpingo-oophorectomy, a significant difference was found in the relationship between ovarian metastasis and deep cervical stromal invasion, lymph node metastasis, and parametrial invasion. The meta-analysis showed that clinical stage IIB vs I-IIA (odds ratio, 4.64; 95% confidence interval, 2.11-10.23), deep stromal invasion (odds ratio, 10.63; 95% confidence interval, 3.12-36.02), lymph node metastasis (odds ratio, 8.54; 95% confidence interval, 4.15-17.57), corpus uteri invasion (odds ratio, 7.39; 95% confidence interval, 3.69-14.78), and parametrial invasion (odds ratio, 9.72; 95% confidence interval, 4.67-20.22) were significantly related to ovarian metastasis. CONCLUSION: Ovarian preservation has no effect on prognosis in women with early-stage cervical adenocarcinoma. Risk factors for ovarian metastases were stage IIB, deep cervical stromal invasion, lymph node metastasis, corpus uteri invasion, and parametrial invasion. In women with early-stage cervical adenocarcinoma without these risk factors, ovarian conservation can be considered.
Safety of Ovarian Preservation in Young Patients with Early-Stage Endometrial Cancer: A Retrospective Study and Meta-Analysis

Chaoyang Sun,Gang Chen,Zongyuan Yang,Jie Jiang,Xingsheng Yang,Na Li,Bo Zhou,Tao Zhu,Juncheng Wei,Danhui Weng,Ding Ma,Changyu Wang,Beihua Kong

DOI: https://doi.org/10.1016/j.fertnstert.2013.05.032

IF: 6.7

2013-01-01

Fertility and Sterility

Abstract:Objective: To evaluate the impact of ovarian preservation on overall survival in young women with early-stage endometrial cancer.Design: Retrospective and meta-analysis.Setting: Two medical centers.Patient(s): A total of 203 patients diagnosed with endometrial cancer (<= 45 years) from 2000 until 2010.Intervention(s): Patients who underwent oophorectomy versus those whose ovaries were preserved.Main Outcome Measure(s): The overall survivals were compared. Independent factors that may affect the patients' survival were extracted and analyzed. A meta-analysis of the literature was carried out to further validate the findings.Result(s): Of 203 young patients, 169 patients (83.3%) underwent bilateral salpingo-oophorectomy, 20 patients had both ovaries preserved, and 14 patients had a single ovary preserved. Multivariate logistic regression identified intraoperative extrauterine disease as the most significant risk factor of ovarian involvement. A Kaplan-Meier curve and Cox proportional hazards models analyses found that ovarian preservation had no effect on overall survival. The findings were validated by meta-analysis.Conclusion(s): Ovarian preservation has no statistically significant impact on the overall survival of young patients with early-stage endometrial cancer. The ovaries should be preserved in this specific population after a thorough preoperative evaluation and an extensive intraoperative exploration. ((C) 2013 by American Society for Reproductive Medicine.)
Ovarian Preservation In Young Patients With Stage I Cervical Adenocarcinoma A Surveillance, Epidemiology, And End Results Study

Jiangtao Lyu,Tingting Sun,Xianjie Tan

DOI: https://doi.org/10.1097/IGC.0000000000000231

2014-01-01

International Journal of Gynecological Cancer

Abstract:Objectives: Although a large part of patients with cervical adenocarcinoma are young, oophorectomy is commonly performed in those who receive hysterectomy for fear of ovarian metastasis. The purpose of this study was to examine the safety of ovarian preservation in young women with cervical adenocarcinoma.Methods: Patients 45 years or younger with stage I cervical adenocarcinoma and adenosquamous carcinoma were identified in the Surveillance, Epidemiology, and End Results program (1988-2007). The characteristics of the patients with ovarian preservation were compared with those of the women with oophorectomy. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazards model were used to explore the effects of ovarian preservation on survival.Results: The study sample consisted of 1639 women, including 1062 women (64.8%) who underwent oophorectomy and 577 women (35.2%) who had ovarian preservation at the time of hysterectomy. Younger age (P < 0.001), recent diagnosis (P < 0.001), low-grade (P < 0.001) and smaller tumor (P < 0.001), white population (P = 0.015), as well as less chance to undergo lymphadenectomy (P < 0.001) and adjuvant radiotherapy (P = 0.041) were associated with ovarian preservation. Ovarian preservation had no effect on either cancer-specific (hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.50-1.61) or overall (HR, 0.81; 95% CI, 0.49-1.33) survival in the Cox proportional hazards model. When the patients without radiotherapy were separately analyzed, the effect on either cancer-specific (HR, 1.24; 95% CI, 0.44-3.54) or overall (HR, 0.77; 95% CI, 0.35-1.73) survival were not statistically significant.Conclusions: Ovarian preservation may have oncological safety for young women with stage I cervical adenocarcinoma.
Retrospective analysis on coexisting ovarian cancer in 976 patients with clinical stage I endometrial carcinoma.

Zimin Pan,Xinyu Wang,Xiaofei Zhang,Xiaoduan Chen,Xing Xie

DOI: https://doi.org/10.1111/j.1447-0756.2010.01354.x

2011-01-01

Journal of Obstetrics and Gynaecology Research

Abstract:Aim: To evaluate the safety of ovarian preservation at the time of operation in clinical stage I endometrial carcinoma. Material and Methods: The data of patients with and without coexisting ovarian cancers were retrospectively collected and clinic-pathologic parameters were analyzed. Results: In total, 20 (2.05%) were histologically diagnosed as coexisting ovarian cancer, including 17 (1.74%) ovarian metastases and three (0.31%) synchronous ovarian primary cancers in 976 patients. Fifty percent (10 of 20) were microscopic ovarian involvements. Ovarian involvement was significantly associated with histological type, depth of myometrial invasion, cervical invasion, uterine serosa extension, fallopian tube involvement, retroperitoneal lymph node metastasis, positive peritoneal cytology and CA125 level by univariate analysis (all P < 0.05); while cervical invasion, uterine serosa extension, and fallopian tube involvement were independent high-risk factors by multivariate analysis (both P < 0.05). Conclusion: The incidence of coexisting ovarian cancer in clinical stage I endometrial carcinoma is low, but the decision for ovary preservation at the time of operation still needs to be made with caution because of occult ovarian metastasis, especially for patients with high-risk factors.
Conservative treatment of endometrial cancer in women of reproductive age (Review)

Maria Zoi Bourou,Alkis Matsas,Thomas Vrekoussis,Georgios Mastorakos,Georgios Valsamakis,Theodoros Panoskaltsis

DOI: https://doi.org/10.3892/mco.2023.2651

2023-05-25

Molecular and Clinical Oncology

Abstract:Endometrial cancer is the fifth most common female cancer worldwide and the third leading female cancer in the Western world. The marked surge in endometrial cancer incidence is alarming. The aim of the present review is to focus on endometrial cancer affecting young women of reproductive age. Surgery, namely abdominal or laparoscopic hysterectomy, with or without salpingo-oophorectomy, and sentinel lymph node detection has become the standard surgical strategy for early stage endometrioid endometrial cancer. However, premenopausal women might want to preserve their fertility, especially if they are nulliparous or have not reached their desired number of children at the time of diagnosis. Conservative, uterus-sparing treatment, based on progestin products, may be an advantageous option for patients meeting the necessary criteria. Potential candidates have to be committed to following a rigorous protocol of treatment, investigations and follow-up. The evidence in favor of this approach, although limited, is encouraging and patients who have achieved a histologically documented disease complete remission could attempt to conceive spontaneously or with the immediate use of assisted reproductive technology techniques. The risk of partial or negative response to progestin treatment or cancer recurrence is well documented, thus patients have to be aware of the possible need for interruption of conservative treatment and hysterectomy.
The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis

Wonkyo Shin,Sang-Yoon Park,Sokbom Kang,Myong Cheol Lim,Sang-Soo Seo

DOI: https://doi.org/10.1186/s13048-020-00698-5

2020-08-22

Journal of Ovarian Research

Abstract:Abstract Purpose We investigated the effect of ovary preserving surgery in early International Federation of Obstetrics and Gynecology (FIGO) stage endometrial cancer patients. Methods Medical records were retrospectively reviewed for 539 patients who were diagnosed with early stage endometrial cancer between Jan 2006 and Dec 2017. Patients were categorized into ovary preservation and ovary removal groups. Demographics, recurrence free survival (RFS), and five-year overall survival (OS) rate were compared, and the clinical factors affecting survival were evaluated by univariate and multivariate analysis. Results The median follow-up period was 85 months (range, 6–142 months), and the median age was 52.7 years. The mean age was higher in the ovary removal group than in the ovary preservation group (54.4 vs 40.94 years; P < 0.001). The ovary preservation group showed an earlier FIGO stage than the ovary removal group ( P = 0.0264). There was a greater incidence of adjuvant chemotherapy administration in the removal group. There were no statistical differences in other baseline characteristics. When comparing the RFS and OS rates, there were no statistical differences between the preservation and removal groups. (recurrence free rate 98.5% vs 92.7%, p = 0.4360 , and 5-year survival rate 98.6% vs 93.0%, p = 0.0892 , respectively). Endometrioid histology ( p = 0.006 ) and post-operative adjuvant chemotherapy ( p = 0.0062 ) were related to OS, and adjuvant chemotherapy ( p < 0.001 ) and radiotherapy ( p = 0.005 ) were related to RFS. Conclusions Ovary preservation in early stage endometrial cancer is worth considering, as it does not affect survival in early stage endometrial cancer patients.

reproductive biology
The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching

Ting Hou,Yidi Sun,Junyi Li,Chenglin Liu,Zhen Wang,Yixue Li,Yuan Lu

DOI: https://doi.org/10.2174/1386207320666170417145856

2017-01-01

Combinatorial Chemistry & High Throughput Screening

Abstract:BACKGROUND Most patients with early stage endometrial endometrioid adenocarcinoma (EEAC) are treated with hysterectomy and bilateral oophorectomy. But this surgical menopause leads to long-term sequelae for premenopausal women, especially for young women of childbearing age. This population-based study was to evaluate the safety of ovarian preservation in young women with stage I EEAC. METHODS Patients of age 50 or younger with stage I EEAC were explored from the Surveillance, Epidemiology and End Results program database during 2004 to 2013. Propensity score matching was used to randomize the data set and reduce the selection biases of doctors. Univariate analysis and multivariate cox proportional hazards model were utilized to estimate the safety of ovarian preservation. RESULTS A total of 7183 patients were identified, and ovarian preservation was performed in 863 (12 %) patients. Compared with women treated with oophorectomy, patients with ovarian preservation significantly tend to be younger at diagnosis (P-value < 0.001) and more likely diagnosed as stage IA EEAC, to have better differentiated tumor tissues and smaller tumors, as well as less likely to undergo radiation and lymphadenectomy. 863 patients treated with oophorectomy were selected by propensity score matching. After propensity score matching, the differences of all characteristics between ovarian preservation and oophorectomy were not significant and potential confounders in the two groups decreased. In univariate analysis of matched population, ovarian preservation had no effect on overall (P-value=0.928) and cancer-specific (P-value=0.390) mortality. In propensityadjusted multivariate analysis, ovarian preservation was not significantly associated with overall (HR=0.69, 95%CI=0.41-1.68, P-value=0.611) and cancer-specific (HR=1.65, 95%CI=0.54-5.06, Pvalue= 0.379) survival. CONCLUSION Ovarian preservation is safe for young women with stage I EEAC, which is not significantly associated with overall and cancer-specific mortality.
Safety and prognosis of ovarian preservationin young women with early-stage endometrial cancer

Yong-xue WANG,Ying JIN,Yan LI,Ling-ya PAN

DOI: https://doi.org/10.16352/j.issn.1001-6325.2017.04.002

2017-01-01

Abstract:Objective The aim of this study is to evaluate the safety and prognosis of ovarian preservation in young women with early-stage endometrial cancer.Methods Women≤45 years of age with stageⅠendometrial cancer recorded from Jan 2005 to Dec 2011 in Peking Union Medical College Hospital were examined.They were further divided into two groups: ovarian preservation group and oophorectomy group.Clinical and pathological recording of these patients were compared.Results A total of 72 women, including 25 patients (34.7%) who had ovarian preservation, were identified.The ovarian preservation group was younger (P=0.007) and had a lower prevalence of lymphadenectomy (P<0.001).While there were no significant difference in stage, tumor grade, the invasion depth of myometrium and adjuvant treatment between two groups (all P>0.05).Of seventy-two cases, five patients relapsed and all survived after a median follow-up time of 89 months (rang: 7-131 months).The Kaplan-Meier curve and the log rank test showed no difference in recurrence-free survival (P=0.194).In Cox model analysis, ovarian preservation had no effect on recurrence-free survival(HR=3.08, 95% CI 0.54-18.44).Conclusions Ovarian preservation in young women with early-stage endometrial cancer is safe and has no negative effect on recurrence-free survival or overall survival.
Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study.

Tianjiao Lyu,Lu Guo,Xiaojun Chen,Nan Jia,Chao Gu,Menghan Zhu,Yuqing Zhao,Xiaoxia Liu,Weiwei Feng

DOI: https://doi.org/10.1177/0300060518822432

2019-01-01

Journal of International Medical Research

Abstract:Objective This study aimed to retrospectively investigate the safety of ovarian preservation of premenopausal women with stage 1a endometrial carcinoma. Methods We performed a population-based study to identify surgically treated stage Ia endometrial cancer of premenopausal women who were diagnosed between August 1989 and December 2015 in our center. Survival outcomes and recurrence rate were examined for premenopausal women who underwent ovarian preservation. Recurrence-free survival rates were calculated following generation of Kaplan-Meier curves and were compared with the log-rank test. Cox regression analysis was performed to identify the independent factors affecting the recurrence rate. Results Patients with ovarian preservation tended to be significantly younger at diagnosis, have less myometrial invasion, and were less likely to undergo lymphadenectomy compared with women treated with bilateral salpingo-oophorectomy. There was no significant difference in recurrence-free survival between the two groups. In the Cox regression model, ovarian preservation remained an independent prognostic factor for improved overall survival. Conclusion Ovarian preservation does not have a negative effect on oncological outcomes. Ovarian preservation can be applied to premenopausal women with stage Ia endometrial carcinoma.
Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues.

G. Lamichhane,T. R. Raghunand,N. Morrison,Samuel C. Woolwine,S. Tyagi,K. Kandavelou,W. Bishai

DOI: https://doi.org/10.1086/508288

2006-11-01

Abstract:The in vivo rate of proliferation of Mycobacterium tuberculosis, the causative agent of tuberculosis, has been linked to the rate of progression and severity of disease. Here, we report that deletion of the gene MT2175 (Rv2115c), a putative mycobacterial proteasome-associated AAA-ATPase, leads to a reduction in the growth rate of M. tuberculosis in vitro and in vivo. Despite the reduced growth, the mutant persisted, with slow and gradual clearance in mouse lungs. The mutant elicited reduced levels of interferon-gamma production in the lungs and, when used as an immunizing agent, provided significant protection against challenge with a virulent strain of M. tuberculosis. Expression of the genes lat and MT3159 were highly up-regulated in the mutant. Thus, loss of MT2175 slows both in vitro and in vivo growth rates and compromises the lethality of M. tuberculosis in mice but has a minimal impact on the organism's ability to persist in host tissues.
Should Ovaries Be Removed or Not in Early-Stage Cervical Adenocarcinoma: a Multicenter Retrospective Study of 105 Patients

Jun Hu,Xiaobing Jiao,Zhifeng Yang,Heng Cui,Hongyan Guo,Yumei Wu,Lirong Zhu

DOI: https://doi.org/10.1080/01443615.2017.1323198

2017-01-01

Journal of Obstetrics and Gynaecology

Abstract:The study population consisted of 105 patients with stage IA to IIB cervical adenocarcinoma (AC) who underwent radical hysterectomy and pelvic lymphadenectomy from three institutions between 1994 and 2015, including 86 patients with bilateral salpingo-oophorectomy (BSO) and 19 patients with ovarian preservation operation. Ovarian metastasis were diagnosed in 3 of 86 patients in BSO group with an incidence rate of 3.5% (3/86). Among the 19 patients with ovarian preservation, none developed an ovarian recurrence in the follow-up (2-71 months). The 5-year overall survival rate of the BSO group and ovarian preservation group were 88.6% and 100%, respectively, with no significant difference (p = .266 > .05). FIGO stage was an independent risk factor of ovarian metastasis for cervical AC (p = .000 < .05). So we concluded that ovarian preservation in young women with early-stage cervical AC may be safe and not associated with an increased risk of overall mortality. IMPACT STATEMENT There has been long-running considerable controversy regarding ovarian preservation in women with cervical AC. The incidence of ovarian metastasis in AC varies significantly from 0% to 12.9%. There were few studies regarding the prognosis and risk factors of cervical AC patients with ovarian preservation. No preoperative selection criteria of ovarian preservation in cervical AC have been officially recommended. In our study of 105 patients with stage IA to IIB cervical AC, the overall ovarian metastasis rate was 3.5% (3/86), and the incidence was 1.5% (1/66) with stage IA to IB. The 5-year overall survival rate of 19 cervical adenocarcinoma patients with ovarian preservation was 100%, and no ovarian recurrence was observed during the follow-up. Our univariate analysis with clinicopathologic variables revealed that only FIGO stage was the risk factor associated with ovarian metastasis of cervical AC. Our data implied that ovarian preservation in young women with early-stage cervical AC might be safe and not associated with an increased risk of overall mortality. Considering the deleterious effects of surgical castration on the long-term quality and quantity of life, we hold that ovarian preservation should be seriously considered in the surgical management of premenopausal women with early-stage cervical AC.
Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis

Xin-yu Liu,Hui Li,R. Hu,Liping Gu,Zunpan Fan,Yuling Liu

DOI: https://doi.org/10.1097/IGC.0000000000001164

2017-11-14

International Journal of Gynecologic Cancer

Abstract:Objectives The aim of this study was to investigate the different efficacies of various fertility-preserving therapies for grade 1 presumed stage IA endometrial cancer. Methods We searched the major online databases (PubMed, MEDLINE, Cochrane Library, Web of Science, and Ovid) and retrieved all the research on fertility-preserving treatment for young, grade 1 presumed stage IA endometrial adenocarcinoma patients since January 2000. We used the systemic evaluation of the Cochrane Collaboration to select the literature and merge the data we collected using R3.2.2 software (R Development Core Team, Auckland, New Zealand). By comparing the remission, recurrence, and pregnancy rates, we evaluated the efficiency of 3 existing fertility-preserving treatments indirectly: a) taking oral progestin only therapy, b) hysteroscopic resection followed by progestin therapy, and c) intrauterine progestin therapy: levonorgestrel-releasing intrauterine system combined with gonadotropin-releasing hormone agonist/progestin therapy. Results Twenty-eight studies met the selection criteria. A total of 619 cases were included in this study. The group that took oral progestin only (456 patients) achieved a complete remission rate (CRR), recurrence rate (ReR), and pregnancy rate (PregR) of 76.3%, (95% confidence interval [CI], 70.7%–81.1%); 30.7% (95% CI, 21.0%–42.4%); and 52.1% (95% CI, 41.2%–66.0%), respectively. The hysteroscopic resection followed by progestin therapy group (73 patients) achieved a CRR, ReR, and PregR of 95.3% (95% CI, 87.8%–100%); 14.1% (95% CI, 7.1%–26.1%); and 47.8% (95% CI, 33.0%–69.5%), respectively. The intrauterine progestin therapy group (90 patients) achieved a CRR, ReR, and PregR of 72.9% (95% CI, 60.4%–82.5%); 11.0% (95% CI, 5.1%–22.0%); and 56.0% (95% CI, 37.3%–73.1%), respectively. Conclusions The existing results show that patients who received hysteroscopic resection followed by progestin therapy achieved the highest CRR. Patients who received oral progestin only might be more likely to recur and have more systemic adverse effects. Recent intrauterine progestin therapy such as levonorgestrel-releasing intrauterine system combined with gonadotropin-release hormone receptor agonist/progestin have a satisfactory PregR and low ReR rate. Considering the inherent limitations of the studies we included, further well-designed, randomized controlled trials are necessary to confirm and update this analysis.

Medicine
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Amanda N Fader,James Java,Meaghan Tenney,Stephanie Ricci,Camille C Gunderson,Sarah M Temkin,Nick Spirtos,Christina L Kushnir,Michael L Pearl,Oliver Zivanovic,Krishnansu S Tewari,David O'Malley,Ellen M Hartenbach,Chad A Hamilton,Natalie S Gould,Robert S Mannel,William Rodgers,Joan L Walker

DOI: https://doi.org/10.1016/j.ygyno.2016.10.016

Abstract:Objectives: We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. Methods: This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Of the 2600 patients enrolled in LAP-2, 753 patients had high-grade UC: 350 had ENDO, 289 had USC, 42 had CC and 72 had CS. Compared with the ENDO cohort, those with other high-grade subtypes were older (p<0.001) and were more likely to have positive peritoneal cytology (p<0.001), positive lymph nodes (p=0.05) and higher disease stage on final pathology (p<0.001). With a median follow-up time of 60months, compared to patients with ENDO, those with USC, CCC and CS subtypes had higher recurrence rates (p<0.001), extra-pelvic recurrences (p<0.001) and poorer PFS (p<0.001) and OS (p<0.001). Those diagnosed with USC and CS experienced the worst survival outcomes (p=0.003). Patterns of recurrence and survival were not different in those staged with LSC vs LAP. On multivariable analysis, age, stage, pelvic washings and Type II histology were independently and adversely associated with survival. Conclusions: Women with apparent early-stage, USC and CS histologies have poorer outcomes than women with grade 3 endometrioid adenocarcinoma. Patterns of recurrence and survival were not impacted by surgical approach.
Investigation of Ovarian Preservation in Young Patients with Endometrial Carcinoma of Clinical StageI

ZHANG Yu,YE Min-juan,YANG Yue-bo,CHENG Juan,LI Xiao-mao

DOI: https://doi.org/10.3877/cma.j.issn.1673-5250.2010.06.003

2010-01-01

Abstract:Objective To investigate the approach of ovarian preservation by analyzing the retrospective data of adnexal metastasis in young patients with endometrial carcinoma of clinical stageⅠ. Methods The pathological type,histological grade,depth of myometrial invasion,lymph node metastasis and adnexal metastasis in endometrial carcinoma patients who were clinically diagnosed stageⅠand treated from January 2000 to December 2009 in the department of Obstetrics and Gynecology,Third Affiliated Hospital,SUN Yat-sen University were retrospectively reviewed and analyzed.The study protocol was approved by the Ethical Review Board of Investigation in Third Affiliated Hospital,SUN Yat-sen University.Informed consent was obtained from all participants.Results There had no significant difference in the rate of adnexal metastasis between endometrioid adenocarcinoma and adenosquamous carcinoma(P0.05).There was significantly statistics difference in the rate of adnexal metastasis among the histological grades of G1 and G2(P0.01),and also significantly different among the non-myometrial invasion,superficial myometrial invasion and deep myometrial invasion(P0.01).With lymph node metastasis and without lymph node metastasis rate of adnexal metastasis can not be compared.Conclusion Adnexal metastasis was related with histological grade and depth of myometrial invasion in the patients with endometrial carcinoma clinically diagnosed stageⅠ.The ovary may be preserved cautiously in young endometrial carcinoma patients with histological G1 and non-myometrial invasion.
Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer.

Jia Peng,Zhang Yan

DOI: https://doi.org/10.18632/oncotarget.18404

2017-01-01

Oncotarget

Abstract:We searched Medline, Embase, Cochrane library, the Chinese Biomedicine Literature Database, the Chinese Scientific Journal Full-text Database, the Chinese Journal Full-text Database, and the Wanfang Database to collect observational studies on the effects of ovary-saving surgery in comparison to bilateral salpingo-oophorectomy (BSO) in young patients with early-stage endometrial cancer (EC). The literature search included studies up to March 2017, and 10 retrospective cohort studies met our selection criteria. Random and fixed effect models revealed that ovarian preservation (OP) was associated with better overall survival (OS) (hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.57-0.99, P = 0.044), and was not associated with reduced recurrence-free survival (RFS) in pre-menopausal patients with early-stage endometrial cancer (HR 1.22, 95% CI 0.32-4.72, P = 0.648; risk ratio [RR] 1.11, 95% CI 0.59-2.10, P = 0.745). Preservation of the ovaries appears to be a safe option with significant benefit for this low risk population after a thorough preoperative evaluation and extensive intraoperative exploration.
Ten-Year Results of Postoperative Adjuvant Treatment In Women With Stage I Endometrial Cancer

Peiying Fu,Ting Zhou,Pengfei Cui,Shixuan Wang,Ronghua Liu

DOI: https://doi.org/10.21203/rs.3.rs-858396/v1

2021-09-28

Abstract:Abstract Background: It remains controversial whether postoperative adjuvant treatment is beneficial for the survival of patients after surgery for early-stage endometrial cancer. To evaluate whether postoperative adjuvant treatment is beneficial for the survival of patients after surgery for early-stage endometrial cancer. We analyzed the outcomes of patients treated with radiotherapy, chemotherapy, or progestagen combined with other adjuvant treatments. Methods: We retrospectively examined disease-free survival (DFS), overall survival (OS) and high risk factors that affected the survival status of all patients who received different postoperative adjuvant therapies. Results: The total relapse and mortality rates were 5.57% and 1.68%, respectively. During follow-up period, fourteen patients (7.29%) developed isolated local recurrence, and 2 patients died (1.04%) of recurrence. The 5-year DFS and OS rates in all patients were 95.83% and 93.75%, respectively. No significant differences were observed in the 5-year DFS, 5-year OS, OS, or DFS among the four groups of patients with FIGO stage I endometrial cancer. The differences in the log-rank test results of the estimates of the 5-year DFS, 5-year OS, DFS and OS of patients with different disease stages and different ages were all significant, but no differences were observed in these parameters between patients with varying degrees of differentiation. Histologic grade, CA125 level, ER and PR status and whether adjuvant therapies had no significant effect on the DFS and OS of all patients according to univariate and multivariate regression analyses, but age stratification did reveal significant differences in DFS and OS in the univariate and multivariate analyses. Conclusion: This retrospective study showed that adjuvant treatments after surgery were not significantly associated with improved DFS or OS in patients with early-stage endometrial cancer. However, FIGO stage and age affected the survival of patients with stage I endometrial cancer.
Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years

Ji Son,Caitlin Carr,Meng Yao,Milena Radeva,Anju Priyadarshini,Jessica Marquard,Chad M Michener,Mariam AlHilli

DOI: https://doi.org/10.1136/ijgc-2019-001105

2020-03-25

International Journal of Gynecologic Cancer

Abstract:Objective Endometrial cancer in pre-menopausal patients aged ≤40 years is rare and poses both diagnostic and management challenges. The goal of this study was to investigate the clinical and pathologic factors associated with endometrial cancer in this group and their impact on survival. Methods Patients with endometrial cancer treated between January 2004 and August 2016 were retrospectively reviewed. Patients who underwent either primary surgical treatment or fertility-sparing therapy were included. Exclusion criteria were age >60 years and patients who received neoadjuvant chemotherapy or primary radiation. Age at diagnosis was used to classify patients into two groups: ≤40 and 41–60 years. Clinical and pathologic variables were compared between the groups. Progression-free survival and overall survival were estimated using Cox proportional hazards. Results A total of 551 patients were evaluated, of which 103 (18.7%) patients were ≤40 years and 448 (81.3%) were 41–60 years. Age ≤40 years was associated with higher body mass index (38.8 vs 35.8 kg/m 2 , p=0.008), non-invasive cancers (54.2% vs 32.6%, p<0.001), lower uterine segment involvement (27.2% vs 22.5%, p<0.001), and less lymphovascular space invasion (16.8% vs 29.1%, p=0.015). The rate of synchronous ovarian cancer was 9.2% vs 0.7% in age 41–60 years (p<0.001), and 19% of women with endometrial cancer aged ≤40 years underwent fertility-sparing therapy. Grade, stage, myometrial invasion, lymphovascular space invasion, and lymph node status were associated with survival, and fertility-sparing therapy adversely affected the recurrence rate of the age ≤40 years cohort. Among all patients aged ≤60 years, mismatch repair deficiency due to MLH1 methylation was associated with worse progression-free survival, 48.6% vs 83.3% (HR 1.98, 95% CI 1.06 to 3.17, p=0.032), and overall survival, 56.5% vs 90.0% (HR 2.58, 95% CI 1.13 to 5.90, p=0.025). Conclusions Patients aged ≤40 years with endometrial cancer have more favorable prognostic factors and higher rates of synchronous tumors. Fertility-sparing therapy was associated with higher recurrence rates. The prognostic value of MLH1 methylation in this population warrants further investigation.
Postoperative Adjuvant Treatment in Women with Stage I Endometrial Cancer: A Retrospective Study

Peiying Fu,Haiying Sun,Ting Zhou,Pengfei Cui,Shixuan Wang,Ronghua Liu

DOI: https://doi.org/10.1155/2023/4007616

IF: 2.6

2023-03-31

International Journal of Clinical Practice

Abstract:Objective. To evaluate whether postoperative adjuvant treatment is beneficial for patient survival after surgery for early stage endometrial cancer (EC). We analyzed the outcomes of patients treated with radiotherapy, chemotherapy, or progestagen combined with other adjuvant treatments. Methods. We analyzed the outcomes of patients treated with radiotherapy alone, chemotherapy alone, or progestagen treatment with other adjuvant treatments. Women without any adjuvant treatment after operation were used as controls. We retrospectively examined disease-free survival (DFS), overall survival (OS), and high-risk factors that affected the survival status of all patients who received different postoperative adjuvant therapies. Results. In all 192 patients, the total relapse and mortality rates were 5.57% and 1.68%, respectively. Fourteen patients (7.29%) developed isolated local recurrence, and 2 patients died (1.04%) of recurrence during the follow-up period. The 5-year DFS and OS rates of all patients were 95.83% and 93.75%, respectively. No significant differences were observed in the 5-year DFS, 5-year OS, OS, or DFS among the four groups of patients with FIGO stage I endometrial cancer ( P = 0.9849 , 0.7430, 0.9754, and 0.4534, respectively). The differences in the log-rank test results of the estimates of the 5-year DFS, 5-year OS, DFS, and OS of patients with different disease stages and different ages were all significant, but no differences were observed in these parameters among patients with varying degrees of differentiation. Histologic grade, CA125 level, ER and PR status, and adjuvant therapy had no significant effect on the DFS and OS of all patients according to univariate and multivariate regression analyses, but a significant effect on DFS and OS was found when the patients were stratified by age. Conclusion. This retrospective study showed that adjuvant therapy after surgery was not significantly associated with improved DFS or OS in patients with early stage endometrial cancer. However, FIGO stage and age affected the survival of patients with stage I endometrial cancer.

medicine, general & internal
Management and Survival of Elderly and Very Elderly Patients with Endometrial Cancer: An Age-Stratified Study of 1228 Women from the FRANCOGYN Group

Clothilde Poupon,Sofiane Bendifallah,Lobna Ouldamer,Geoffroy Canlorbe,Emilie Raimond,Nina Hudry,Charles Coutant,Olivier Graesslin,Cyril Touboul,Pierre Collinet,Alexandre Bricou,Cyrille Huchon,Emile Daraï,Marcos Ballester,Jean Levêque,Vincent Lavoue

DOI: https://doi.org/10.1245/s10434-016-5735-9

IF: 4.339

2016-12-22

Annals of Surgical Oncology

Abstract:BackgroundLittle data exist about the clinical management and survival of elderly patients with endometrial cancer. This study aimed to evaluate the management of elderly and very elderly patients with endometrial cancer as well as the overall survival (OS) rate, disease-free survival (DFS) rate, and cancer-specific survival (CSS) rate in a multicenter cohort.MethodsData from 1228 patients with endometrial cancer who received primary treatment between January 2001 and December 2012 were collected from a multicenter database. Clinical management, DFS, CSS, and OS were analyzed.ResultsBased on the international endometrial cancer risk classification, 36% (212/582) of women age 65 years or younger, 42% (220/526) of women ages 65–80 years, and 48% (58/120) of women older than 80 years showed high-risk endometrial cancer (p < 0.001). Pelvic lymphadenectomy was performed for 85% (230/271) of the women age 65 years or younger and 46% (33/71) of the women older than 80 years (p < 0.001). Radiotherapy was performed for 27% (33/120) of the very elderly and 40% (233/582) of the young patients (p = 0.009). The 3-year CSS rates were 95% (95% confidence interval [CI], 93–97%) for the women age 65 years or younger, 90% (95% CI, 87–94%) for the women ages 65–80 years, and 82% (95% CI, 73–93%) for the women older than 80 years (p < 0.001).ConclusionsThe elderly and very elderly patients with endometrial cancer showed poorer prognosis than young patients. The significant lower CSS rate for the elderly patients could have be due to both the higher rate of high-risk endometrial cancer and undertreatment. Specific guidelines for the management of elderly and very elderly patients with endometrial cancer are needed to improve their prognosis.

oncology,surgery
Uterine sparing management in patients with endometrial cancer: a narrative literature review

Maria Zisi,Dimitrios Zygouris,Orestis Tsonis,Sofia Papadimitriou,Mastorakos George,Sophia Kalantaridou,Minas Paschopoulos

DOI: https://doi.org/10.1080/01443615.2021.2006164

2022-01-06

Journal of Obstetrics and Gynaecology

Abstract:Endometrial cancer is the most common malignancy of the female genital tract. Approximately 25% of cases occur in premenopausal women, and up to 5% of cases occur in women who are younger than 40 years old. The survival rate in these cases is 99%; therefore, uterine-sparing management could be considered under strict criteria selection and the strong desire of the woman to preserve uterus and fertility. Diagnosis should be performed after a hysteroscopic biopsy instead of dilatation and curettage. The highest remission rate was achieved after combining a hysteroscopic resection with hormonal therapy compared to single hormonal treatment. The most common regiments are the following progestins: megestrol acetate (MA) and medroxyprogesterone acetate (MPA) taken orally with a daily dosage of 160 mg-320 mg for MA and 250 mg-600 mg for MP. Evaluations at three and six months could be performed by office endometrial biopsy and/or hysteroscopic directed biopsy especially in the presence of levonorgestrel intrauterine system, and in cases of remission, either a pregnancy attempt or maintenance therapy should be considered. After childbearing, hysterectomy with bilateral salpingo-oophorectomy is recommended, whereas ovarian preservation could be considered depending on the patient's age and whether they fulfil the strict criteria selection.

obstetrics & gynecology

Human papillomavirus is commonly present in psoriatic skin and normal skin samples from healthy subjects.

Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: A retrospective study and meta-analysis.

Safety of Ovarian Preservation in Young Patients with Early-Stage Endometrial Cancer: A Retrospective Study and Meta-Analysis

Ovarian Preservation In Young Patients With Stage I Cervical Adenocarcinoma A Surveillance, Epidemiology, And End Results Study

Retrospective analysis on coexisting ovarian cancer in 976 patients with clinical stage I endometrial carcinoma.

Conservative treatment of endometrial cancer in women of reproductive age (Review)

The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis

The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching

Safety and prognosis of ovarian preservationin young women with early-stage endometrial cancer

Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study.

Deletion of a Mycobacterium tuberculosis proteasomal ATPase homologue gene produces a slow-growing strain that persists in host tissues.

Should Ovaries Be Removed or Not in Early-Stage Cervical Adenocarcinoma: a Multicenter Retrospective Study of 105 Patients

Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis

Investigation of Ovarian Preservation in Young Patients with Endometrial Carcinoma of Clinical StageI

Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer.

Ten-Year Results of Postoperative Adjuvant Treatment In Women With Stage I Endometrial Cancer

Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years

Postoperative Adjuvant Treatment in Women with Stage I Endometrial Cancer: A Retrospective Study

Management and Survival of Elderly and Very Elderly Patients with Endometrial Cancer: An Age-Stratified Study of 1228 Women from the FRANCOGYN Group

Uterine sparing management in patients with endometrial cancer: a narrative literature review